JULIE DYREK: Open Payments
NPI 1427668748 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,800 in 74 payments from 13 companies in 2025. Trend: 2023 $1,901 · 2024 $1,157 · 2025 $2,800
Food & beverage: $2,700Education: $100
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $575 |
| Alkermes, Inc. | 14 | $348 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $328 |
| Teva Pharmaceuticals USA, Inc. | 5 | $247 |
| Vanda Pharmaceuticals Inc. | 2 | $243 |
| ABBVIE INC. | 8 | $236 |
| E.R. Squibb & Sons, L.L.C. | 5 | $194 |
| Janssen Pharmaceuticals, Inc | 1 | $150 |
| Indivior Inc. | 1 | $125 |
| PFIZER INC. | 1 | $116 |
Products named: CAPLYTA, ABILIFY MAINTENA, REXULTI, FANAPT, VRAYLAR, LYBALVI, COBENFY, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
